Navigation Links
Cambrex Reports Second Quarter of 2011 Results
Date:8/2/2011

and Development ("R&D") Expenses decreased to $2.6 million in the second quarter of 2011 from $2.8 million in the second quarter of 2010.

Operating Profit increased to $7.3 million in the second quarter of 2011 from $6.9 million in the second quarter of 2010.  The increase in Operating Profit was driven primarily by higher sales volumes and lower production costs partially offset by lower pricing and unfavorable foreign exchange.

Net Interest Expense decreased to $0.6 million in the second quarter of 2011 from $1.2 million in the second quarter of 2010.  This decrease is primarily due to the maturing of the Company's higher fixed interest rate swaps in October 2010.

The Provision for Income Taxes totaled $1.9 million in the second quarter of 2011.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

Income from continuing operations for the second quarter of 2011 was $4.8 million or $0.16 per share compared to $3.7 million or $0.12 per share in the second quarter of 2010.

Capital expenditures and depreciation for the second quarter of 2011 were $3.0 million and $5.8 million compared to $2.4 million and $5.2 million in the second quarter of 2010, respectively.

Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased with our second quarter and year to date performance with sales volumes significantly higher year over year.  Similar to the first quarter, we saw increases in revenues for some of our larger custom manufacturing products and continued strong orders for our generic APIs.  Although profit margins were negatively impacted by foreign exchange, tiered pricing arrangements and production inefficiencies at one of our plants, a continued focus on cost reductions helped mitigate thos
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cambrex Reports Third Quarter 2010 Results
2. Cambrex Reports Fourth Quarter and Full Year 2009 Results
3. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
4. Cambrex Reports First Quarter 2009 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports Third Quarter 2008 Results
7. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
8. Gen-Probe Reports Financial Results for the Second Quarter of 2011
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , ... August 26, 2015 , ... ... announces today that a second US laboratory is to open in Manhattan, Kansas ... the continued partnership and long-term growth of research and development through collaboration with ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... , August 26, 2015 ... factors fueling the optimism in biotech,s forecast is ... and life sciences advancements.  Active biotechnology & healthcare ... BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, ... Knapp, Wis. The company has added a AS16 Sharples centrifuge to harvest products ... during bacterial or fungal fermentation process development. , The new centrifuge greatly ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... cells is vital for our bodies to function. Part ... called neurotransmitters. The vesicle fuses with the nerve cell ... the next nerve cell. It is crucial that new ... continuously to take place. If parts of this communication ...
... Cleveland Clinic initiates dosing in ASSERT Trial , TSX ... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today ... Phase 2 clinical trial lead by Cleveland Clinic. This ... for the treatment of atherosclerosis, in patients with stable ...
... , SHANGHAI, Dec. 22 ... in China, announced today that,the company has received 2009 Deloitte ... year to win this award. The news was,announced at a ... Kong. , The Deloitte Technology Fast ...
Cached Biology Technology:New insight in nerve cell communication 2Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 2Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 3Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 4
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... at the University of Toronto, The Hospital for Sick ... British Columbia have identified a new treatment target for ... estimated 10% of common colds. The virus, called human ... reason for hospitalization of infants and children under two ...
... August 16th issue of Developmental Cell , researchers at ... that new blood vessels form in the right place and ... long time that blood vessels branch to give rise to ... this branching occurs with a reproducible pattern. However, the mechanisms ...
... A study out of York University has some refreshing ... Published today in the journal Applied Physiology, Nutrition and ... otherwise healthy live just as long as their slim counterparts, ... "Our findings challenge the idea that all obese individuals ...
Cached Biology News:Researchers map pathway of infection for a common, potentially life-threatening respiratory virus 2Fat and healthy? York U study finds slim isn't always superior 2
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Request Info...
Recombinant Mouse Wnt-3a...
... There are at least 20 structurally ... of the TGF-beta superfamily. BMPs were originally ... bone formation. They are also involved in ... organs. BMPs regulate the growth, differentiation, chemotaxis ...
Biology Products: